Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00109889 · ClinicalTrials.gov registry record · Phase 2
S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00109889 is a Phase 2 study that was terminated before completion, run by SWOG Cancer Research Network. The registered enrollment target is 2 participants.
The verdict
NCT00109889, a Phase 2 study, was terminated before completion, sponsored by SWOG Cancer Research Network.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI) and fludeoxyglucose F 18 positron emission tomography (\^18FDG-PET) may help diagnose solitary plasmacytoma. PURPOSE: This clinical trial is studying MRI and \^18FDG-PET to see how well they work in diagnosing patients with solitary plasmacytoma.
Interventions
- PROCEDURE positron emission tomography
- PROCEDURE magnetic resonance imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2005-04 |
| Est. Completion | 2007-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00109889
The ClinicalTrials.gov registry entry for NCT00109889 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which positron emission tomography is the first listed.
NCT00109889 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00109889 about?
NCT00109889 is a clinical study titled "S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma". RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI) and fludeoxyglucose F 18 positron emission tomography (\^18FDG-PET) may help diagnose solitary plasmacytoma. PURPOSE: This clinical trial is studying MRI and \^18FDG-PET to see how well they work in diagnosing patients with ...
What is the current status of trial NCT00109889?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2005-04. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00109889?
The interventions under investigation include: positron emission tomography (PROCEDURE), magnetic resonance imaging (PROCEDURE).
Who is sponsoring clinical trial NCT00109889?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.